Back
Asilomar and recombinant DNA - NobelPrize.org
webnobelprize.org·nobelprize.org/prizes/chemistry/1980/berg/article/
Frequently referenced in AI governance discussions as a historical analogy for voluntary research pauses and proactive safety governance; relevant to debates about whether AI development should adopt similar moratorium or self-regulation approaches.
Metadata
Importance: 72/100opinion pieceprimary source
Summary
Paul Berg's Nobel Prize article recounts the 1975 Asilomar Conference, where scientists voluntarily paused recombinant DNA research to assess biosafety risks and establish guidelines. The article serves as a historical case study of scientific self-governance in response to emerging biotechnology risks. It is frequently cited as a precedent for how the scientific community can proactively address dual-use and safety concerns in powerful new technologies.
Key Points
- •The 1975 Asilomar Conference brought together scientists to voluntarily pause recombinant DNA experiments and assess potential biohazards before proceeding.
- •Scientists initiated a self-imposed moratorium on certain experiments, demonstrating that researchers themselves can take responsibility for managing emerging risks.
- •The conference produced guidelines that were later formalized into NIH regulations, showing a pathway from voluntary norms to institutional governance.
- •Asilomar is widely cited as a model for proactive scientific governance when a technology's risks are uncertain but potentially significant.
- •The episode raises questions about the limits of voluntary self-regulation and whether similar approaches could apply to AI and other transformative technologies.
Cited by 1 page
| Page | Type | Quality |
|---|---|---|
| Pause Advocacy | Approach | 91.0 |
Cached Content Preview
HTTP 200Fetched Mar 15, 202619 KB
Asilomar and recombinant DNA - NobelPrize.org
You are using an outdated browser. Please upgrade your browser to improve your experience and security.
Skip to content
Enhanced Page Navigation
Paul Berg: Asilomar and Recombinant DNA
Navigate to:
Summary -- Facts -- Biographical -- Curriculum Vitae -- Nobel Prize lecture -- Banquet speech -- Interview -- Photo gallery -- Article -- Other resources - Walter Gilbert - Frederick Sanger Press release Award ceremony speech
Asilomar and recombinant DNA
by Paul Berg
1980 Nobel Prize laureate in chemistry
26 August 2004
Introduction
Advances in the life sciences, particularly in biomedicine, are increasingly being scrutinized and their acceptance questioned. Novel technologies and ideas that impinge on human biology and their perceived impact on human values have renewed strains in the relationship between science and society. Thirty years ago, nations were engaged in debates about whether recombinant DNA research, also referred to as gene splicing and genetic engineering, was too dangerous to be allowed to continue. Fears of creating new kinds of plagues or of altering human evolution or of irreversibly altering the environment were only some of the concerns that were rampant. Lingering doubts and concerns still persist about the use of that technology in the development of genetically modified plants and animals used as food. Notably, some nations have enacted legislation that prohibits genetically-modified plants and animals from entering into their food supply. Paradoxically, no such embargo exists for the drugs and therapies that have revolutionized the treatment of serious diseases although many of them were created with the same technologies.
Today, it is research with human embryonic stem cells and attempts to prepare cloned stem cells for research and medical therapies that are being disavowed as being ethically unacceptable. As with the GM food controversy and other cases where science and public policy clash, there are repeated calls to convene an “Asilomar Conference” to examine and resolve the policy controversies.
Unique conference
The lofty status of the Asilomar Conference and the deliberative process it spawned stems from its success in identifying, evaluating and ultimately mitigating the perceived risks of recombinant DNA. Looking back now, this unique conference marked the beginning of an exceptional era for science and for the public discussion of science policy. Its success permitted the then contentious technology of recombinant DNA to emerge and flourish. Now the use of the recombinant DNA technology dominates research in biology. It has altered both the way questions are formulated and the way solutions are sought. The isolation of genes from any organ
... (truncated, 19 KB total)Resource ID:
15cfe9a1d2dda83b | Stable ID: Mjc5ZWVkNj